ProPhase Labs Announces Progress In BE-Smart Esophageal Cancer Test Development USPTO Grants Additional Broad Patents For BE-SMART
Portfolio Pulse from Happy Mohamed
ProPhase Labs, Inc. (NASDAQ:PRPH) announced progress in the development of its BE-SMART esophageal cancer diagnostic test, including the grant of broad patents by the USPTO and positive preliminary results from additional specimen analyses. The test, aimed at detecting early signs of cancer in individuals with Barrett's esophagus, is nearing the end of its clinical studies, with a commercial launch targeted for 2024. The test has shown over 99% molecular precision and has been tested on over 200 human samples. ProPhase Labs plans to commercialize BE-SMART as a laboratory-developed test (LDT), with potential wide-scale adoption targeting over 20 million Americans monitored for Barrett's esophagus.
February 20, 2024 | 1:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ProPhase Labs, Inc. (NASDAQ:PRPH) announced significant progress in the development and potential commercialization of its BE-SMART esophageal cancer diagnostic test, including the grant of broad patents and positive preliminary results.
The announcement of progress in the BE-SMART test development, including the grant of broad patents and positive preliminary results, is likely to be viewed positively by investors. The nearing completion of clinical studies and the targeted commercial launch in 2024 highlight the company's advancements in cancer diagnostics. The potential market impact, given the test's high precision and the target market of over 20 million Americans, could significantly enhance ProPhase Labs' revenue prospects and position in the diagnostics market.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100